# A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Study · id `cardio:ct-nct05179876` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05179876](<https://clinicaltrials.gov/study/NCT05179876>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05179876

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.

## Technical summary

Registry record NCT05179876. Non-randomized; no masking; primary purpose treatment. Start 2022-05-04 (actual); primary completion 2027-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT05179876, source copy `cardio:ctgov-nct05179876-2026-11-03`, retrieved 2026-11-18)
- Started: 2022-05-04 (actual) (ClinicalTrials.gov record NCT05179876, source copy `cardio:ctgov-nct05179876-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2027-01-31 (anticipated) (ClinicalTrials.gov record NCT05179876, source copy `cardio:ctgov-nct05179876-2026-11-03`, retrieved 2026-11-18)
- Completion: 2033-09-28 (anticipated) (ClinicalTrials.gov record NCT05179876, source copy `cardio:ctgov-nct05179876-2026-11-03`, retrieved 2026-11-18)
- Countries: Belarus; Belgium; Bulgaria; China; Hungary; Poland; Russia; South Africa; South Korea; Taiwan; Thailand; Ukraine; Vietnam (ClinicalTrials.gov record NCT05179876, source copy `cardio:ctgov-nct05179876-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05179876-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
- Acronym: PLATYPUS
- Condition: Hypertension, Pulmonary
- Intervention (Drug): Macitentan
- Intervention (Drug): Selexipag
- Intervention (Drug): Macitentan/Tadalafil FDC
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: 699a31407a9740155c89830848b109ae6dbe5e4c5fdf22b1137478e32889f5d0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
